Moberg Pharma announces outcome of rights issue of ordinary shares
STOCKHOLM, 31 May 2022. The Board of Directors of Moberg Pharma AB (publ) (OMX: MOB) (“Moberg Pharma” or the “Company”) today announces the outcome of the fully guaranteed rights issue of ordinary shares with preferential rights for Moberg Pharma’s shareholders (the “Rights Issue”) which was resolved upon by the Board of Directors on 8 April 2022 and approved by an extraordinary general meeting on 3 May 2022. In total, 24,305,220 ordinary shares were subscribed for with support of subscription rights, corresponding to approximately 46.3 percent of the Rights Issue. 775,636 ordinary shares,